..., and oteracil potassium (S-1) have been used in advanced PC after gemcitabine (GEM) plus nab-paclitaxel treatment, but the clinical difference between nal-IRI+5-FU/LV and S-1 remains unclear. Methods: We retrospectively compared the efficacy and safety of nal-IRI+5-FU/LV and S-1 in patients with advanced PC...

...: The multicenter randomized phase III KHBO1401 study (gemcitabine+cisplatin+S-1 [GCS] vs. GC in biliary tract cancers [BTC]) demonstrated that GCS not only prolonged patient survival but also achieved a high response rate and that it should be good for neoadjuvant therapy. Therefore, to explore the possibilities...

... aimed to evaluate the effectiveness and safety of adjuvant gemcitabine plus S-1 (GS) chemotherapy after curative surgical resection for BTC. Methods: 225 BTC patients who underwent surgical resection between January 2006 and May 2019 were enrolled in this study. Twenty-seven patients received adjuvant...

... a low dose of irinotecan given as a long-term infusion is expected to enhance antitumor activity. We conducted a randomized phase II study to compare oral S-1 with a 24-h infusion of irinotecan plus bevacizumab versus FOLFIRI plus bevacizumab. Methods: The subjects comprised 120 chemotherapy-naïve...

... combined with HER2-directed agents such as trastuzumab and lapatinib is supported by some evidence. The combination of T-DM1 and S-1, another oral 5-FU, may be a safe alternative treatment for metastatic breast cancer. Objectives: The optimal dose of S-1 was evaluated in combination with T-DM1 for patients...

... Objective: To evaluate the efficacy and safety of alternate-day administration of S-1 as second-line chemotherapy for unresectable pancreatic cancer in a multicenter, randomized, phase II study. Methods: Patients with histologically proven, unresectable pancreatic cancer treated with chemotherapy...

... (SCCE). The observed increased toxicity of the DCF regimen, however, was clinically harmful. S-1, an oral anticancer drug, has been approved as a combination therapy for SCCE, and alternate-day regimen with S-1 has shown lower levels of toxicity. This prospective single-center phase I/II trial examines...

... of neoadjuvant chemotherapy prior to gastrectomy. Methods: Two cycles of a 3-week regimen of fluoropyrimidine S-1 (40 mg/m 2 , orally, twice daily), together with cisplatin (60 mg/m 2 , intravenously, day 8), were administered to patients, separated by a 2-week rest period. Surgery was performed 3 weeks later...

...Sotaro Sadahiro; Toshiyuki Suzuki; Akira Tanaka; Kazutake Okada; Gota Saito; Akemi Kamijo Objectives: Protracted low-dose infusion of irinotecan has been suggested to enhance antitumor activity. A phase II study was conducted to evaluate the safety and efficacy of oral S-1 combined with 24-hour...

...Sotaro Sadahiro; Toshiyuki Suzuki; Akira Tanaka; Kazutake Okada; Gota Saito; Akemi Kamijo; Takeshi Akiba; Shuichi Kawada Objective: A single-arm phase II clinical trial was conducted to evaluate the safety and efficacy of preoperative chemoradiotherapy (CRT) with concurrent S-1, bevacizumab...

... of the Clinical Study Group of Osaka University (CSGO), Colorectal Group Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted...

... and efficacy of concurrent chemoradiotherapy (CCRT) combined with an orally active fluoropyrimidine, S-1, plus cisplatin for locally advanced esophageal cancer (LAEC). Methods: CCRT comprised 2 courses, a 30-Gy radiotherapy over 3 weeks plus daily oral S-1 (80 mg/m 2 /day) for 2 weeks and a 24-hour cisplatin...

...Yasunori Akutsu; Tsuguaki Kono; Masaya Uesato; Isamu Hoshino; Kazuo Narushima; Toshiharu Hanaoka; Toru Tochigi; Yoshihide Semba; Wei Qin; Hisahiro Matsubara Purpose: S-1 is widely used for various cancers. It may be useful for esophageal squamous cell carcinoma (ESCC); however...

... prognostic score composed of C-reactive protein and albumin, for patients with advanced cancer. Methods: A total of 83 advanced gastric cancer patients receiving biweekly docetaxel/S-1 treatment (DS) were included in the study. To identify the value of GPS as prognostic factor for disease-specific survival...

... Research and Education Objective: S-1 is effective in sequential combination with irinotecan (IRIS) in treating metastatic colorectal cancer. We conducted a randomized phase II trial of modified leucovorin, fluorouracil and irinotecan (mFOLFIRI) + bevacizumab and sequential IRIS + bevacizumab as first...

...Yuichi Ando; Kenji Kawada; Megumi Inada; Sachi Morita; Ayako Mitsuma; Yoshinari Yasuda; Mariko Hiramatsu; Yasushi Fujimoto; Ken-ichi Fujita Objective: This pharmacokinetic study of S-1 was conducted in patients in whom glomerular filtration rate (GFR) was directly measured to explore...

...Yoon Hee Choi; Tae Won Kim; Kyu-Pyo Kim; Sung Sook Lee; Yong Sang Hong; Min-Hee Ryu; Jae-Lyun Lee; Heung Moon Chang; Baek-Yeol Ryoo; Ho-Sook Kim; Jae-Gook Shin; Yoon-Koo Kang Objectives: We investigated the efficacy and safety of the combination of irinotecan (CPT-11) and S-1 (IRIS regimen...

...Sotaro Sadahiro; Toshiyuki Suzuki; Akira Tanaka; Kazutake Okada; Akemi Kamijo; Chieko Murayama; Takeshi Akiba; Yuko Nakayama Purpose: To assess the maximum tolerability of a combination of S-1 and preoperative radiotherapy and to evaluate the feasibility and activity in patients with locally...

... Objective: Platinum-free regimens can represent an alternative for advanced non-small cell lung cancer (NSCLC) if similar efficacy is provided with better tolerability. This study evaluated the efficacy and safety of combined irinotecan and S-1 for chemotherapy-naïve advanced NSCLC. Methods: Chemotherapy...

...Ki Y. Chung; Kaku Saito; Christopher Zergebel; Ellen Hollywood; Michal Segal; Leonard B. Saltz Background: S-1 is a novel oral agent combining the 5-fluorouracil (FU) prodrug tegafur with gimeracil and oteracil, which inhibit 5-FU degradation by dihydropyrimidine dehydrogenase and phosphorylation...